Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BYNature Medicine

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

19 more authors
23 affiliations
  1. 1The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [email protected]
  2. 2Division of Medical Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Republic of Korea
  3. 3Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  4. 4Yale School of Medicine, New Haven, CT, USA
  5. 5National Cancer Center, Gyeonggi-do, Republic of Korea
  6. 6University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA
  7. 7University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA
  8. 8Washington University School of Medicine, St. Louis, MO, USA
  9. 9START San Antonio, San Antonio, TX, USA
  10. 10Department of Medicine, University of Chicago, Chicago, IL, USA
  11. 11Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
  12. 12Vall d'Hebron Institute of Oncology, Barcelona, Spain
  13. 13Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel
  14. 14The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
  15. 15Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea
  16. 16Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
  17. 17Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
  18. 18Department of Internal Medicine, Chonnam National University Medical School, and Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea
  19. 19Hospital Universitario 12 de Octubre and Universidad Complutense, Madrid, Spain
  20. 20Section of Hematology-Oncology, Department of Medicine, Hanyang University Medical Center, Hanyang University, Seoul, Republic of Korea
  21. 21National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
  22. 22AbbVie Inc., North Chicago, IL, USA
  23. 23START Midwest, Grand Rapids, MI, USA

Abstract

Seizure-related homolog 6 (SEZ6) is expressed in small cell lung cancer (SCLC) and neuroendocrine neoplasms. In an open label, phase 1 trial, ABBV-706, an antibody−drug conjugate with a SEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i), was administered intravenously every 3 weeks (Q3W) to 288 patients with advanced solid tumors; 240 received monotherapy, including 124 with relapsed/refractory (R/R) SCLC. Primary objectives of dose escalation (part 1, advanced solid tumors), dose optimization and expansion (part 2, R/R SCLC only) and dose expansion (part 4, central nervous system tumors and high-grade neuroendocrine neoplasms only) were to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 monotherapy and, from parts 1 and 2, to determine the recommended phase 2 dose (RP2D) of ABBV-706 in R/R SCLC. In the monotherapy cohort ( N = 240), the most common treatment-related adverse events (TRAEs) at any grade were anemia (61%) and fatigue (38%). Grade 3 or higher TRAEs occurred in 61% of patients and were dose dependent (39% at 1.8 mg kg −1 and 70% at 2.5 mg kg −1 ). In the R/R SCLC monotherapy cohort ( n = 124), any-grade and grade 3 or higher TRAEs occurred in 93% and 61% of patients, respectively. ABBV-706 demonstrated promising preliminary efficacy in patients with R/R SCLC, with an objective response rate (ORR) of 52% (65/124). In patients with R/R SCLC receiving monotherapy in dose optimization and expansion part 2, ORR was similar between 1.8 mg kg −1 and 2.5 mg kg −1 doses (56% (23/41) and 59% (23/39), respectively), with a duration of response that was highest at the 1.8 mg kg −1 dose and with most patients achieving rapid and durable tumor reduction. Although exploratory, long-term efficacy measures were an important consideration in the RP2D determination, and in R/R SCLC monotherapy, overall survival (OS) was highest at the 1.8 mg kg −1 dose, with a median OS of 12.4 months. Based on the totality of available data, including, but not limited to, safety, preliminary efficacy measures and PK, 1.8 mg kg −1 Q3W was confirmed as the optimal RP2D for patients with R/R SCLC. ClinicalTrials.gov: NCT05599984 .

Related

  1. 535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)
    Yi-Long Wu, Hai-jun Guo, Chongrui Xu +5
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. 548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors
    Ignacio Garcia-Ribas, Maloy Ghosh, Sanghamitra Bhattacharjee +6
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. Quantitative Systems Pharmacology Model for Trop-2 Targeting Antibody-Drug Conjugate in Triple-Negative Breast Cancer
    S. Dogru, A. Suresh, E. P. Bowman +3
    bioRxivPreprintCC BY-NC-NDFull textPharmacology & toxicologybioRxiv
  4. Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models
    Shraddha Subramanian, Peyton C. High, Cara Guernsey-Biddle +7
    bioRxivPreprintCC BY-NDFull textOncologybioRxivPMC
  5. A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors
    Yuxiang Ma, Yufeng Guo, Shuang Deng +16
    Journal of Hematology & OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
BibTeX
@article{byers2026sez6targeting,
  title = {{SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial}},
  author = {Lauren A. Byers and Byoung Chul Cho and Alissa Jamie Cooper and Anne C. Chiang and Ji‐Youn Han and Muhammad Furqan and Afshin Dowlati and Daniel Morgensztern and Kyriakos P. Papadopoulos and Noura J. Choudhury and María Vieito and Jair Bar and Joo-Hang Kim and Wallace Akerley and Tae Jeong Kim and Young‐Chul Kim and Luis G Paz-Ares and Myung‐Ju Ahn and Hiroshi Yokouchi and Darius Meiman and Wijith P. Munasinghe and Oluwadamilola Ogunyankin and Nadine S. Jahchan and Song Wang and Cristiano Ferlini and Randy R. Robinson and Frederick J. Kohlhapp and Tammy L. Palenski and Guillermo Rivell and Pooja Hingorani and Sreenivasa Chandana},
  journal = {Nature Medicine},
  year = {2026},
  month = jun,
  doi = {10.1038/s41591-026-04452-0},
  url = {https://doi.org/10.1038/s41591-026-04452-0},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
AU  - Lauren A. Byers
AU  - Byoung Chul Cho
AU  - Alissa Jamie Cooper
AU  - Anne C. Chiang
AU  - Ji‐Youn Han
AU  - Muhammad Furqan
AU  - Afshin Dowlati
AU  - Daniel Morgensztern
AU  - Kyriakos P. Papadopoulos
AU  - Noura J. Choudhury
AU  - María Vieito
AU  - Jair Bar
AU  - Joo-Hang Kim
AU  - Wallace Akerley
AU  - Tae Jeong Kim
AU  - Young‐Chul Kim
AU  - Luis G Paz-Ares
AU  - Myung‐Ju Ahn
AU  - Hiroshi Yokouchi
AU  - Darius Meiman
AU  - Wijith P. Munasinghe
AU  - Oluwadamilola Ogunyankin
AU  - Nadine S. Jahchan
AU  - Song Wang
AU  - Cristiano Ferlini
AU  - Randy R. Robinson
AU  - Frederick J. Kohlhapp
AU  - Tammy L. Palenski
AU  - Guillermo Rivell
AU  - Pooja Hingorani
AU  - Sreenivasa Chandana
PY  - 2026
DA  - 2026/06/01
JO  - Nature Medicine
DO  - 10.1038/s41591-026-04452-0
UR  - https://doi.org/10.1038/s41591-026-04452-0
AB  - Seizure-related homolog 6 (SEZ6) is expressed in small cell lung cancer (SCLC) and neuroendocrine neoplasms. In an open label, phase 1 trial, ABBV-706, an antibody−drug conjugate with a SEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i), was administered intravenously every 3 weeks (Q3W) to 288 patients with advanced solid tumors; 240 received monotherapy, including 124 with relapsed/refractory (R/R) SCLC. Primary objectives of dose escalation (part 1, advanced solid tumors), dose optimization and expansion (part 2, R/R SCLC only) and dose expansion (part 4, central nervous system tumors and high-grade neuroendocrine neoplasms only) were to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 monotherapy and, from parts 1 and 2, to determine the recommended phase 2 dose (RP2D) of ABBV-706 in R/R SCLC. In the monotherapy cohort ( N = 240), the most common treatment-related adverse events (TRAEs) at any grade were anemia (61%) and fatigue (38%). Grade 3 or higher TRAEs occurred in 61% of patients and were dose dependent (39% at 1.8 mg kg −1 and 70% at 2.5 mg kg −1 ). In the R/R SCLC monotherapy cohort ( n = 124), any-grade and grade 3 or higher TRAEs occurred in 93% and 61% of patients, respectively. ABBV-706 demonstrated promising preliminary efficacy in patients with R/R SCLC, with an objective response rate (ORR) of 52% (65/124). In patients with R/R SCLC receiving monotherapy in dose optimization and expansion part 2, ORR was similar between 1.8 mg kg −1 and 2.5 mg kg −1 doses (56% (23/41) and 59% (23/39), respectively), with a duration of response that was highest at the 1.8 mg kg −1 dose and with most patients achieving rapid and durable tumor reduction. Although exploratory, long-term efficacy measures were an important consideration in the RP2D determination, and in R/R SCLC monotherapy, overall survival (OS) was highest at the 1.8 mg kg −1 dose, with a median OS of 12.4 months. Based on the totality of available data, including, but not limited to, safety, preliminary efficacy measures and PK, 1.8 mg kg −1 Q3W was confirmed as the optimal RP2D for patients with R/R SCLC. ClinicalTrials.gov: NCT05599984 .
SN  - 1078-8956
SN  - 1546-170X
SN  - 1744-7933
ER  -